

Sith Sathornsumetee

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7827149/publications.pdf>

Version: 2024-02-01

60
papers

9,119
citations

136950
32
h-index

149698
56
g-index

60
all docs

60
docs citations

60
times ranked

9460
citing authors

#	ARTICLE	IF	CITATIONS
1	Oligosarcomas, IDH-mutant are distinct and aggressive. Acta Neuropathologica, 2022, 143, 263-281.	7.7	18
2	Assessment of therapeutic effect of CD20-targeted immunoliposome in primary central nervous system lymphoma. Biomedicine and Pharmacotherapy, 2022, 150, 112979.	5.6	2
3	Immune checkpoint inhibitor in recurrent hypermutated glioblastoma with POLE mutation. Neuro-Oncology Advances, 2021, 3, vdab093.	0.7	3
4	Simplified approach for pathological diagnosis of diffuse gliomas in adult patients. Pathology Research and Practice, 2021, 223, 153483.	2.3	6
5	Nanostructured lipid base carrier for specific delivery of garlic oil through blood brain barrier against aggressiveness of glioma. Journal of Drug Delivery Science and Technology, 2021, 64, 102651.	3.0	7
6	Active targeting liposome-PLGA composite for cisplatin delivery against cervical cancer. Colloids and Surfaces B: Biointerfaces, 2020, 196, 111270.	5.0	37
7	An open-label, multicenter, phase II study of ceritinib in patients with advanced ALK+ non-lung solid tumors and hematological malignancies (ASCEND-10).. Journal of Clinical Oncology, 2020, 38, 3520-3520.	1.6	1
8	Brainstem dysfunction heralding disseminated cryptococcosis. Clinical Neurology and Neurosurgery, 2018, 167, 62-64.	1.4	2
9	Characterization of liposome-containing SPIONs conjugated with anti-CD20 developed as a novel theranostic agent for central nervous system lymphoma. Colloids and Surfaces B: Biointerfaces, 2018, 161, 497-507.	5.0	47
10	Effect of spinal tap test on the performance of sit-to-stand, walking, and turning in patients with idiopathic normal pressure hydrocephalus. Nagoya Journal of Medical Science, 2018, 80, 53-60.	0.3	10
11	ALSUntangled No. 37: Inosine*. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2017, 18, 309-312.	1.7	1
12	Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial. Lancet Oncology, The, 2017, 18, 1373-1385.	10.7	776
13	P40: Gait alteration in patients with Idiopathic Normal Pressure Hydrocephalus after cerebral spinal fluid removal. Gait and Posture, 2017, 57, 256-257.	1.4	0
14	High Carbonic Anhydrase-9 Expression Identifies a Subset of 1p/19q Co-Deletion and Favorable Prognosis in Oligodendroglioma. World Neurosurgery, 2016, 91, 518-523.e1.	1.3	2
15	Targeting Netrin-1 in glioblastoma stem-like cells inhibits growth, invasion, and angiogenesis. Tumor Biology, 2016, 37, 14949-14960.	1.8	12
16	Teaching Neuro <i>Images</i> : Erdheim-Chester disease (polyostotic sclerosing histiocytosis). Neurology, 2015, 85, e79-80.	1.1	0
17	ALS Untangled No. 20: The Deanna Protocol. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2013, 14, 319-323.	1.7	19
18	Diagnostic performance of advanced MRI in differentiating high-grade from low-grade gliomas in a setting of routine service. Journal of the Medical Association of Thailand = Chotmaihet Thangphaet, 2013, 96, 1365-73.	0.1	4

#	ARTICLE	IF	CITATIONS
19	Molecularly targeted therapy in neuro-oncology. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2012, 104, 255-278.	1.8	9
20	Bevacizumab continuation beyond initial bevacizumab progression among recurrent glioblastoma patients. British Journal of Cancer, 2012, 107, 1481-1487.	6.4	83
21	Phase II study of Gleevec plus hydroxyurea in adults with progressive or recurrent low-grade glioma. Cancer, 2012, 118, 4759-4767.	4.1	26
22	Phase 1 trial of dasatinib plus erlotinib in adults with recurrent malignant glioma. Journal of Neuro-Oncology, 2012, 108, 499-506.	2.9	41
23	Outcome after bevacizumab clinical trial therapy among recurrent grade III malignant glioma patients. Journal of Neuro-Oncology, 2012, 107, 213-221.	2.9	24
24	Twisted tango: brain tumor neurovascular interactions. Nature Neuroscience, 2011, 14, 1375-1381.	14.8	70
25	Phase I study of sunitinib and irinotecan for patients with recurrent malignant glioma. Journal of Neuro-Oncology, 2011, 105, 621-627.	2.9	62
26	Therapeutic Strategies to Target Multiple Kinases in Glioblastoma. Anti-Cancer Agents in Medicinal Chemistry, 2011, 11, 700-711.	1.7	9
27	High-Grade Astrocytomas. , 2011, , 195-232.		0
28	Phase II trial of bevacizumab and erlotinib in patients with recurrent malignant glioma. Neuro-Oncology, 2010, 12, 1300-1310.	1.2	207
29	Treatment and management of malignant gliomas. Nature Reviews Clinical Oncology, 2010, 7, 75-77.	27.6	24
30	Targeting multiple kinases in glioblastoma multiforme. Expert Opinion on Investigational Drugs, 2009, 18, 277-292.	4.1	39
31	Hypoxia-Inducible Factors Regulate Tumorigenic Capacity of Glioma Stem Cells. Cancer Cell, 2009, 15, 501-513.	16.8	1,196
32	Metronomic chemotherapy with daily, oral etoposide plus bevacizumab for recurrent malignant glioma: a phase II study. British Journal of Cancer, 2009, 101, 1986-1994.	6.4	194
33	Designer Therapies for Glioblastoma Multiforme. Annals of the New York Academy of Sciences, 2008, 1142, 108-132.	3.8	91
34	Safety and pharmacokinetics of dose-intensive imatinib mesylate plus temozolomide: Phase 1 trial in adults with malignant glioma. Neuro-Oncology, 2008, 10, 330-340.	1.2	41
35	Targeting Cancer Stem Cells through L1CAM Suppresses Glioma Growth. Cancer Research, 2008, 68, 6043-6048.	0.9	376
36	Bevacizumab Plus Irinotecan in Recurrent WHO Grade 3 Malignant Gliomas. Clinical Cancer Research, 2008, 14, 7068-7073.	7.0	166

#	ARTICLE	IF	CITATIONS
37	Tumor Angiogenic and Hypoxic Profiles Predict Radiographic Response and Survival in Malignant Astrocytoma Patients Treated With Bevacizumab and Irinotecan. Journal of Clinical Oncology, 2008, 26, 271-278.	1.6	259
38	Bevacizumab Plus Irinotecan in Recurrent Glioblastoma Multiforme. Journal of Clinical Oncology, 2007, 25, 4722-4729.	1.6	1,285
39	Phase II Trial of Bevacizumab and Irinotecan in Recurrent Malignant Glioma. Clinical Cancer Research, 2007, 13, 1253-1259.	7.0	1,005
40	Malignant glioma drug discovery “targeting protein kinases. Expert Opinion on Drug Discovery, 2007, 2, 1-17.	5.0	25
41	Antiangiogenic Therapy in Malignant Glioma: Promise and Challenge. Current Pharmaceutical Design, 2007, 13, 3545-3558.	1.9	40
42	Phase II study of Cloretazine for the treatment of adults with recurrent glioblastoma multiforme1. Neuro-Oncology, 2007, 9, 70-74.	1.2	14
43	Diagnosis and Treatment of High-Grade Astrocytoma. Neurologic Clinics, 2007, 25, 1111-1139.	1.8	86
44	Molecularly targeted therapy for malignant glioma. Cancer, 2007, 110, 13-24.	4.1	292
45	Phase II study of imatinib mesylate and hydroxyurea for recurrent grade III malignant gliomas. Journal of Neuro-Oncology, 2007, 83, 53-60.	2.9	92
46	Friday night palsy: an unusual case of brachial plexus neuropathy. Clinical Neurology and Neurosurgery, 2006, 108, 191-192.	1.4	6
47	Signal transduction pathways as novel therapeutic targets in malignant glioma. Future Neurology, 2006, 1, 819-829.	0.5	0
48	New approaches to primary brain tumor treatment. Anti-Cancer Drugs, 2006, 17, 1003-1016.	1.4	45
49	Phase 1 Trial of Gefitinib Plus Sirolimus in Adults with Recurrent Malignant Glioma. Clinical Cancer Research, 2006, 12, 860-868.	7.0	187
50	New treatment strategies for malignant gliomas. Expert Review of Anticancer Therapy, 2006, 6, 1087-1104.	2.4	117
51	Stem Cell-like Glioma Cells Promote Tumor Angiogenesis through Vascular Endothelial Growth Factor. Cancer Research, 2006, 66, 7843-7848.	0.9	1,239
52	AAL881, a Novel Small Molecule Inhibitor of RAF and Vascular Endothelial Growth Factor Receptor Activities, Blocks the Growth of Malignant Glioma. Cancer Research, 2006, 66, 8722-8730.	0.9	54
53	Vandetanib (ZD6474), a novel multitargeted kinase inhibitor, in cancer therapy. Drugs of Today, 2006, 42, 657.	1.1	28
54	Phase I trial of irinotecan plus temozolomide in adults with recurrent malignant glioma. Cancer, 2005, 104, 1478-1486.	4.1	76

#	ARTICLE	IF	CITATIONS
55	ZD6474, a Novel Tyrosine Kinase Inhibitor of Vascular Endothelial Growth Factor Receptor and Epidermal Growth Factor Receptor, Inhibits Tumor Growth of Multiple Nervous System Tumors. Clinical Cancer Research, 2005, 11, 8145-8157.	7.0	94
56	Phase II Study of Imatinib Mesylate Plus Hydroxyurea in Adults With Recurrent Glioblastoma Multiforme. Journal of Clinical Oncology, 2005, 23, 9359-9368.	1.6	313
57	Parry-Romberg syndrome with fatal brain stem involvement. Journal of Pediatrics, 2005, 146, 429-431.	1.8	29
58	SB-431542, a small molecule transforming growth factor-beta-receptor antagonist, inhibits human glioma cell line proliferation and motility. Molecular Cancer Therapeutics, 2004, 3, 737-45.	4.1	150
59	Assessment of hindlimb gait as a powerful indicator of axonal loss in a murine model of progressive CNS demyelination. Brain Research, 2000, 877, 396-400.	2.2	19
60	Quantitative Ultrastructural Analysis of a Single Spinal Cord Demyelinated Lesion Predicts Total Lesion Load, Axonal Loss, and Neurological Dysfunction in a Murine Model of Multiple Sclerosis. American Journal of Pathology, 2000, 157, 1365-1376.	3.8	59